<DOC>
	<DOCNO>NCT01070719</DOCNO>
	<brief_summary>This open-label study patient relapse form Multiple Sclerosis design assess biochemical , immunological pharmacokinetic profile large , actively infuse natalizumab patient population . A duration effect progressive multifocal leukoencephalopathy ( PML ) risk associate natalizumab therapy appear exist . There minimal data available understand effect biochemical cellular level . The purpose study gather preliminary data several parameter guide focus research duration effect .</brief_summary>
	<brief_title>Pharmacokinetic , Immunological Biochemical Sample Collection Analysis Tysabri Patient Cohort</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Natalizumab</mesh_term>
	<criteria>1 . Ability understand purpose risk study provide sign date informed consent authorization use protect health information ( PHI ) accordance national local subject privacy regulation . 2 . Aged 18 75 year old , inclusive , time informed consent . 3 . Must patient relapse form Multiple Sclerosis enrol TOUCH Prescribing Program expect discontinue Tysabri® therapy prior completion requirement study . 4 . Must treat monthly IV infusion Tysabri® 300 mg least 1 month . 5 . Must magnetic resonance imaging ( MRI ) brain scan , perform prior initiation treatment Tysabri® , file . 6 . Must weigh 42 126 kg , inclusive . 7 . Fifteen patient 1 month to12 month natalizumab therapy , fifteen patient 24 month natalizumab therapy ask participate TNF alpha subset . Medical History : 1 . History , abnormal laboratory result indicative , clinically significant cardiac , endocrinologic , hematologic , hepatic , immunologic , metabolic , urologic , pulmonary , gastrointestinal , dermatologic , psychiatric , renal , major disease , determine Investigator . 2 . If subject answer 'Yes '' question PML questionnaire resolve prior infusion per standard operating procedure natalizumab infusion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>Multiple Sclerosis , relapse form</keyword>
</DOC>